Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Boston Scientific shares fell Wednesday ... by a 25% sales jump of its cardiovascular products to $2.73 billion. The MedSurg division, which includes endoscopy, urology, and neuromodulation ...

Boston Scientific had increased its debt leverage to acquire new products in 2015-16 and reduced ... electrophysiology, endoscopy, urology, neuromodulation, and other interventional cardiology ...

Investing.com -- Boston Scientific (NYSE:BSX ... also above the $4.04 billion estimated by analysts. Endoscopy net sales were $678 million, a 7.8% year-over-year increase, slightly above the ...

Endoscopy Equipment market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to ...